215 related articles for article (PubMed ID: 33512712)
1. Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma.
Nagase K; Akutagawa T; Rikitake-Yamamoto M; Morito S; Futamata M; Tobu S; Noguchi M; Toda S; Aoki S
J Pathol; 2021 May; 254(1):46-56. PubMed ID: 33512712
[TBL] [Abstract][Full Text] [Related]
2. Oral-specific microenvironments regulate cell behavior and anticancer drug sensitivity of tongue squamous cell carcinoma.
Iwamoto S; Nishiyama M; Kawasaki M; Morito S; Sakumoto T; Toda S; Yamashita Y; Aoki S
Hum Cell; 2023 Mar; 36(2):643-656. PubMed ID: 36715868
[TBL] [Abstract][Full Text] [Related]
3. Microenvironmental elements singularity synergistically regulate the behavior and chemosensitivity of endometrioid carcinoma.
Morito S; Kawasaki M; Nishiyama M; Sakumoto T; Hashiguchi M; Narita T; Kawaguchi A; Toda S; Aoki S
Hum Cell; 2023 May; 36(3):1147-1159. PubMed ID: 36853404
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
[TBL] [Abstract][Full Text] [Related]
5. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
6. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
7. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
9. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
[TBL] [Abstract][Full Text] [Related]
10. Stem cells increase in numbers in perinecrotic areas in human renal cancer.
Varna M; Gapihan G; Feugeas JP; Ratajczak P; Tan S; Ferreira I; Leboeuf C; Setterblad N; Duval A; Verine J; Germain S; Mongiat-Artus P; Janin A; Bousquet G
Clin Cancer Res; 2015 Feb; 21(4):916-24. PubMed ID: 25501128
[TBL] [Abstract][Full Text] [Related]
11. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
14. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
15. RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.
Xiong W; Zhang B; Yu H; Zhu L; Yi L; Jin X
Adv Sci (Weinh); 2021 Sep; 8(18):e2100881. PubMed ID: 34319001
[TBL] [Abstract][Full Text] [Related]
16. Cancer-adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer.
Akutagawa T; Aoki S; Yamamoto-Rikitake M; Iwakiri R; Fujimoto K; Toda S
Gastric Cancer; 2018 Nov; 21(6):946-955. PubMed ID: 29696406
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
18. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.
Zhao T; Zhou Y; Wang Q; Yi X; Ge S; He H; Xue S; Du B; Ge J; Dong J; Qu L; Wang L; Zhou W
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34036385
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
20. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
